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ABSTRACT
It has been shown that neurons alter the expression of astrocytic metabolic 
enzymes by secretion of until now unknown molecule(s) into extracellular fluid. 
Here, we present evidence that neuron-derived transthyretin (TTR) stimulates 
expression of glycolytic enzymes in astrocytes which is reflected by an increased 
synthesis of ATP. The action of TTR is restricted to regulatory enzymes of glycolysis: 
phosphofructokinase P (PFKP) and pyruvate kinase M1/M2 isoforms (PKM1/2). The 
regulation of PFK and PKM expression by TTR is presumably specific for brain tissue 
and is independent of the role of TTR as a carrier protein for thyroxine and retinol. 
TTR induced expression of PKM and PFK is mediated by the cAMP/PKA-dependent 
pathway and is antagonized by the PI3K/Akt pathway. Our results provide the first 
experimental evidence for action of TTR as a neuron-derived energy metabolism 
activator in astrocytes and describe the mechanisms of its action. The data presented 
here suggest that TTR is involved in a mechanism in which neurons stimulate 
degradation of glycogen-derived glucosyl units without significant modulation of 
glucose uptake by glial cells.
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INTRODUCTION
The brain is characterised by very high energy 
requirements and glucose is the main energetic substrate for 
this organ [1]. During the last two decades a growing body 
of evidence has accumulated supporting the hypothesis of 
the astrocyte-neuron lactate shuttle (ANLS) that postulates 
that the majority of glucose taken up by brain from the 
blood stream is utilized by astrocytes which convert it into 
lactate that is used to fulfill energy requirements of neurons 
[2, 3]. It has also been shown that glutamate released by 
active neurons stimulates glycolysis in astrocytes leading 
to the increased production of lactate [2].
The tight coupling between astrocytic metabolism 
and synaptic transmission suggests that these two cell 
types can act as a kind of syncytium, cross-regulating 
expression of proteins involved in energy metabolism 
and neurotransmitter synthesis. In accordance with 
this concept, our previous study has demonstrated that 
co-culturing neurons with astrocytes significantly 
affected the level of mRNA and protein abundance of 
the metabolic enzymes in both cell types. Moreover, 
we have provided evidence that neurons augment the 
expression of astrocytic enzymes both by direct physical 
contact of the cells and by release of, as yet unknown, 
molecule(s) into extracellular fluid [4]. In accordance 
with our results, it has been recently shown that neurons 
may regulate, via Notch signalling, the expression of 
hundreds of astrocytic genes, among them ones involved 
in ANLS, however, the changes were observed only at 
the transcriptome level [5]. 
In the present study, we show the results of 
studies focused on the identification of the regulatory 
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factor(s) released from neurons into extracellular fluid 
and stimulating astrocyte energy metabolism. We 
demonstrate that neuron-released TTR stimulates the 
expression of glycolytic enzymes in astrocytes which 
results in an increased synthesis of ATP. Remarkably, the 
action of TTR is restricted to the regulators of glycolysis, 
phosphofructokinase P (PFKP) and pyruvate kinase M1/
M2 isoforms (PKM1/2).
TTR is an evolutionary conserved [6, 7] carrier 
protein for thyroxine (T4) [8] and retinol [9]. In the brain, 
TTR is mainly synthetized by ependymocytes [10], but 
also by neurons [11] and its receptors are expressed, among 
others, on astrocytes [12]. The role of TTR in the biology of 
the nervous system has been described in several contexts. 
It has been shown to be involved in cognition [13, 14], 
behaviour [15], neuropeptide maturation [16] and nerve 
regeneration [17]. TTR has also been shown to play a 
protective role in Alzheimer’s disease [18, 19] and cerebral 
ischemia [20].
The results presented here reveal that TTR 
modulates glial energy metabolism independently of its 
role as a carrier protein. We also demonstrate that only the 
forms of TTR unsaturated by hormones (T4 and retinol) 
may stimulate the expression of PKM1/2. Moreover, the 
stimulation is mediated by the cAMP-dependent pathway 
and it is antagonized by the PI3K/AKT pathway.
To the best of our knowledge, this is the first report 
identifying the neuron-derived energy metabolism regulator 
of astrocytes and describing its mechanism of action. 
RESULTS
Neuron-derived metabolic regulator(s) are heat 
unstable and with molecular mass between 30 
and 100 kDa
The incubation of astrocytes for 24 and 48 hours 
in the neuron-conditioned medium (CM) significantly 
elevated the level of mRNAs, protein abundance and 
activities for both isozymes of pyruvate kinase (PKM1/2) 
as compared to the cells cultured in the fresh neuronal 
medium (FM) (Figure 1A–1C). Immunofluorescence 
analysis revealed that treatment with the CM did not affect 
the morphology of the cells as compared to unstimulated 
(the FM-treated) astrocytes (Supplementary Figure 2).
To ensure that the observed changes did not result 
from substitution of a standard astrocytic culture medium 
(DMEM/FBS-based) with the neuronal one (neurobasal/ 
B27-based), we compared PKM1/2 expression in both 
the media and we did not find any differences in PKM1/2 
expression (Supplementary Figure 3).
Heat-treatment of the CM samples resulted in the loss 
of the ability of the medium to stimulate PKM1/2 and PFKP 
expression in astrocytes suggesting that the “neuron-derived 
effector” may be a protein or polypeptide (Figure 2E, 2F).
The results of molecular filtration studies demonstrated 
that fraction of the CM containing molecules with the mass 
in the range of 30–100 kDa was able to elevate PKM1/2 
expression in the glial cells (Figure 2A–2C). 
Neuron-derived factor(s) stimulate ATP synthesis 
in astrocytes
Since pyruvate kinase is a regulatory enzyme 
of glycolysis, it might be expected that treatment of 
astrocytes with the CM impact the energy production 
in these cells. To address this issue, astrocytes were 
treated with the CM for 48 h and this increased about 
2-fold the level of ATP as compared to cells incubated in 
the FM medium (Figure 1D). This effect was abolished 
after a heat-treatment of the CM (Figure 2G). A similar 
increase in the ATP level was observed after incubation of 
astrocytes with a fraction of the CM medium containing 
components of the mass below 100 kDa, but not those of 
the mass lower than 30 kDa (Figure 2D).
Transthyretin is detected in neuron-conditioned 
medium
To determine which proteins are released into 
extracellular fluid by neurons, fractions of 30–100 kDa of 
the FM and the CM media were subjected to MS analysis. 
All recorded proteins are presented in Supplementary 
Table 1. Among the proteins detected in the CM medium, 
only transthyretin and enoyl-CoA hydratase domain-
containing protein 3 (ECHDC3) were unique for this 
medium. The molecular mass of ECHDC3 is 33 kDa, and 
the mass of TTR tetramer (a physiological oligomeric 
state of the protein) is 55 kDa. However, ECHDC3 is 
an intracellular protein expressed in mitochondrion and 
its presence in the CM probably resulted from cells 
lysis, thus, TTR was assumed to be the neuron-derived 
metabolic regulator and used in further studies.
Transthyretin is neuron-derived metabolic 
regulator 
Human plasma TTR at physiological concentration 
(20 μg/ml, 36.4 nM) [21, 22] was added to the FM medium 
to test its ability to activate the expression of glycolytic 
enzymes in glial cells. The results of immunofluorescent 
study, FISH experiments and WB analysis revealed that 
TTR elevated the level of PKM1/2 in a similar manner 
to that observed for the CM-activated astrocytes. The 
supplementation of media with TTR did not affect 
the morphology of the cells (Supplementary Figure 2). The 
supplementation of the CM with TTR did not cause further 
increase in the expression of PKM1/2 (Figure 3A–3C). 
To investigate if the stimulating effect of TTR 
was associated with its role as a carrier protein for T4 
and retinol, the FM medium was supplemented with 
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TTR-saturating concentrations (1 μM) of L-thyroxine or 
retinol. As a result, the stimulatory effects of TTR were 
abolished. Moreover, when T4 or retinol were added to the 
CM, the ability of such mixtures to stimulate expression 
of PKM1/2 was abrogated and the level of PKM1/2 was 
practically the same as the FM medium (Figure 3D, 3E). 
From this, it is evident that only the ligand-free TTR 
played a significant role of signalling molecule increasing 
PKM1/2 expression in astrocytes.
To further verify the role of TTR, the CM samples 
were deprived of the protein using immunoprecipitation. 
As it is shown in Figure 3A, 3B such treatment of the CM 
medium resulted in a significant abrogation of the CM 
ability to stimulate the expression of PKM1/2 in astrocytes 
both at mRNA and protein levels (Figure  3A, 3B).
In order to determine which other steps of glycolysis 
in astrocytes were modulated by TTR, the impact of the 
CM and TTR-treatment on the expression of hexokinase 
1 (HK1, which catalyses the first step of glycolysis), 
aldolase A (ALDOA, which catalyses the central reaction 
of glycolysis), PFKP (the second regulatory enzyme 
of glycolysis) and monocarboxylate transporter 4 
(MCT4, the astrocytic lactate transporter) were studied. 
Immunofluorescence analysis revealed that treatment 
with the CM nor TTR did not affect the expression of 
ALDOA and MCT4 as compared to unstimulated (the FM-
treated) astrocytes (Figure 4A, 4C). At the same time, the 
expression of PFKP was affected in a similar manner as 
PKM1/2 (Figure 4D). Interestingly, the expression of HK1 
remained unchanged (Figure 4B). 
To examine the dynamism of TTR modulation, the 
expression of metabolic enzymes in the CM and TTR-
treated cells was studied at different time points. TTR-
induced changes in mRNA level for PFK and PKM were 
observed already after 30 minutes and they progressed 
in time (Supplementary Figure 5A). The changes in the 
proteins expression were much slower since they were 
observed only after 48 h (Supplementary Figure 5B).
To corroborate that TTR acts specifically to glial 
cells, the effect of the CM and TTR on the expression 
of PKM1/2 in non-glial cells was tested. The results of 
immunofluorescent studies revealed no changes in the 
expression of glycolytic enzymes in mouse lung cancer 
cell line (KLN205), human skin fibroblasts, nor human 
immortalized epithelial cells (ME16C) after stimulation 
with TTR (Figure 5).
Figure 1: The effect of the neuron-conditioned medium (CM) on ATP synthesis and the levels of mRNA, protein 
abundance and the activity of pyruvate kinase (PKM1/2) in astrocytes. (A) Subcellular localization of mRNA (right panel) 
and protein (left panel) of PKM1/2 in astrocytes cultured for 24 h or 48 h respectively in the neuron-conditioned medium (CM) or 
the neuronal fresh medium (FM). The nuclei were visualized with DAPI. Bar = 50 μm. (B–D) The effect of CM on: (B) the expression of 
the PKM1/2 protein (left chart) and mRNA (right chart), (C) the activity of PKM1/2, (D) ATP synthesis in astrocytes. The expression of the 
enzyme in cells cultured in the FM medium was assumed to be 100%. Each value represents the mean and S.D. of at least three individual 
experiments. Asterisks (*) indicate statistically significant differences (P < 0.001).
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TTR stimulates PKM1/2 expression via the 
cAMP-dependent pathway and it is antagonized 
by the PI3K/AKT pathway
Searching for cellular secondary messengers of 
TTR (and the whole CM) signalling in astrocytes, several 
activators and inhibitors of proteins kinases crucial for 
regulation of energy metabolism, were examined. The 
results demonstrated that inhibition of FAK, GSK3, and 
PKA in astrocytes treated with TTR or the CM resulted 
in significant reduction of the level of mRNA encoding 
PKM1/2 (Figure 6A–6C) compared to the pure CM. 
Unexpectedly, the inhibition of AKT and PI3K, 
the kinases usually involved in the stimulation of energy/
glucose metabolism, increased the expression of mRNA 
encoding PKM1/2 in the CM and TTR-treated cells 
(Figure 6D, 6E). Inhibition of other studied kinases 
(mTOR, p38) did not change significantly the level of 
mRNA encoding PKM1/2 (Figure 6F, 6G). The inhibition 
of all the above kinases did not affect the expression in the 
FMtreated cells. Similarly, the incubation of astrocytes with 
IGF-I did not affect the level of mRNA encoding PKM1/2 
(Figure 6H) both, in the FM and the CM-treated cell.
In contrast, supplementation of FM with forskolin 
(an activator of adenylyl cyclase) imitated the stimulation 
of the expression observed in the CM. However, the 
supplementation of the CM with forskolin did not enhance 
further the increase in PKM1/2 mRNA level (Figure 6I). 
The similar changes in mRNA level after supplementation 
Figure 2: The effect of filtration (MWCO 30 and 100 kDa) and heat inactivation of the neuron-conditioned medium 
on PKM1/2 and PFKP expression in astrocytes. (A) Subcellular localization of mRNA encoding PKM1/2 in astrocytes cultured for 
24 h in the CM or the FM and the media fractions containing molecules of the mass below 30 kDa (“Filtration 30 kDa”) or below 100 kDa 
(“Filtration 100 kDa”). The nuclei were visualized with DAPI. Bar = 50 μm. (B–D) The effect of filtration (MWCO 30 and 100 kDa) of 
the media on the PKM1/2 protein (B) and mRNA (C) expression and ATP synthesis (D) in astrocytes. (E–G) The effect of heat inactivation 
of the CM (5 min at 45°C–“CM45” or at 65°C – “CM65”) on the level of mRNA for PKM1/2 (E) and PFKP (F) and ATP synthesis (G) in 
astrocytes. The expression of the enzyme in cells cultured in the FM medium was assumed to be 100%. Each value represents the mean and 
S.D. of at least three individual experiments. Asterisks (*) indicate statistically significant differences (P < 0.001).
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of FM with forskolin was observed for PFKP, but not for 
HK1 (Supplementary Figure 6).
DISCUSSION
Studies of the brain energetics have revealed that 
neurons stimulate the expression of glucose metabolism 
proteins in astrocytes [4]. However, a mechanism of this 
phenomenon is not well understood [3, 4]. Recently, we 
have demonstrated that neurons induce genes and proteins 
expression in astrocytes by releasing of some unknown 
molecules into extracellular fluid [4]. On the other hand, 
the study of Hasel et al. has shown that a direct cell-to-
cell contact also activated the transcription of several 
metabolic enzymes [5]. Nevertheless, the latter study 
has not provided any information as to whether the 
observed transcriptional changes were correlated with 
altered protein levels and/or the basal metabolic state of 
astrocytes.
Figure 3: The effect of TTR on PKM1/2 expression in astrocytes. (A–B) The effect of supplementation of the media with 
36.4 nM TTR (+TTR) and depletion of TTR from the media (post-IP) on the subcellular localization (A) and expression of PKM1/2 protein 
(B; left chart) and mRNA (B; right chart) in astrocytes. The nuclei were visualized with DAPI. Bar = 50 μm. (C) Western blot analysis of 
PKM1/2 in extracts (15 μg of total protein per line) of astrocytes cultured for 48 h in the FM and the CM media supplemented with 36.4 nM 
TTR (+TTR); β-actin was used as a loading control. (D–E) The effect of saturation of TTR with 1 μM L-thyroxine, T4 (D) or 1 μM retinol, 
Ret (E) on the expression of the PKM1/2 mRNA (right chart) and protein (left chart) in astrocytes. The expression of the enzyme in cells 
cultured in the FM medium was assumed to be 100%. Each value represents the mean and S.D. of at least three individual experiments. 
Asterisks (*) indicate statistically significant differences (P < 0.001).
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Figure 4: The effect of TTR and the CM on ALDOA, HK1, MCT4 and PFKP expression in astrocytes. The measurement 
of ALDOA (A), HK1 (B), MCT4 (C), PFKP (D) protein-related immunofluorescence in astrocytes cultured for 48 h in the CM and in the 
FM supplemented with 36.4 nM TTR (+TTR). The expression of the enzyme in cells cultured in the FM medium was assumed to be 100%. 
Each value represents the mean and S.D. of at least three individual experiments. Asterisks (*) indicate statistically significant differences 
(P < 0.001).
Figure 5: The effect of the CM and TTR on the expression of PKM1/2 in non-glial cells. The cells were cultured for 48 h 
in the FM or the CM media supplemented with 36.4 nM TTR (+TTR). (A–C, left panels) Subcellular localisation of PKM1/2 in the 
KLN205 (A), human skin fibroblasts (B) and the ME16C cells (C). Right charts in each panel (A–C) show quantitation of PKM1/2-related 
fluorescence. The expression of the enzyme in cells cultured in the FM was assumed to be 100%. Each value represents the mean and S.D. 
of at least three individual experiments. The nuclei were visualized with DAPI. Bar = 50 μm.
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Here, we presented evidence that incubation of 
astrocytes in the neuron-conditioned medium (CM), but 
not the fresh medium (FM), increased the astrocytic levels 
of mRNA and protein and enzymatic activity of pyruvate 
kinase, a regulatory enzyme of glycolysis.
A significant elevation of the ATP level in the CM-
treated astrocytes indicated that neurons stimulate astrocytic 
energy production by releasing of some molecule(s) into 
extracellular fluid. Subsequent set of experiments let us not 
only unequivocally identify transthyretin as the neuron-
derived soluble inducer of glycolytic enzymes expression 
in astrocytes but also demonstrate that the activity of the 
cAMP-dependent signalling pathway is crucial for these 
neuron-dependent changes.
TTR was originally described as a carrier protein 
for T4 and retinol [8, 9]. In the brain, the expression of 
TTR was thought to be restricted to ependymocytes 
[10, 23]. However, recent studies have confirmed neuronal 
synthesis of the molecule [11]. TTR has been shown to 
play an important role in neuronal plasticity, regeneration 
and aging [13–17] but its action as a direct metabolic 
regulator has not been reported thus far. Behavioural 
deficits observed in TTR knockout mice have suggested 
that the roles of this protein are more complex than that 
initially described [13, 24], however, it is noteworthy that 
Figure 6: The effect of the metabolic activation or inhibition of the signalling kinases on the expression of the PKM1/2 
mRNA in astrocytes. The cells were cultured for 24 h in the FM, CM or FM supplemented with 36.4 nM TTR (FM+TTR) media. 
(A–G) The effect of inhibition of signalling kinases with (A) 1 μM FAK inhibitor 14, (B) 5 μM SB216763 (GSK3 inhibitor), (C) 20 μM 
KT5720 (PKA inhibitor), (D) 1 μM AKT inhibitor IV, (E) 2.3 μM wortmannin (PI3K inhibitor), (F) 0.01 μM rapamycin (mTOR inhibitor), 
(G) 50 μM SB202190 (p38 inhibitor) on the expression of mRNA encoding PKM1/2 in astrocytes. mRNA expression in cells cultured in 
the FM medium in the absence of the stimulators or inhibitors was assumed to be 100%. Each value represents the mean and S.D. of at 
least three individual experiments. Asterisks (*) indicate statistically significant differences (P < 0.001). (H–I) The effects of the metabolic 
activators (H) 13 nM IGF-I, (I) 10 μM forskolin on the expression of mRNA encoding PKM1/2 in astrocytes.
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some of mentioned defects appear to be abrogated by the 
administration of retinoic acid [14]. 
Our studies demonstrated that only the hormone-
free TTR acts as an activator of glycolysis in astrocytes 
and saturation of TTR with T4 or retinol abolished the 
stimulatory effect of this protein. This finding suggests that 
TTR is a multifunctional protein and its role in the brain 
biology is not limited to its action as the carrier protein.
The data presented here point to regulatory enzymes 
of glycolysis, PKM1/2 and PFKP, as the main targets of 
TTR action. TTR increased their mRNAs and protein 
expression level; however, changes in mRNA levels were 
much faster than those observed for the protein level. 
The long time lapse between the mRNA and protein 
increase suggests the existence of an additional step in the 
regulation of TTR-dependent expression of PK and PFK.
Moreover, the regulation of metabolic enzymes 
expression by TTR is presumably specific to astrocytes 
as we did not observed any changes in the expression of 
PKM1/2 after TTR-treatment in non-glial cells, such as 
immortalized epithelial cells (ME16C), human fibroblasts, 
or mouse lung cancer cell line (KLN205). 
Taking into account that TTR stimulates the 
expression of PFK and PKM, but not HK, it may be 
presumed that TTR acts as a mediator due to which 
neurons can selectively stimulate oxidation of glucosyl 
units derived from glycogen but not glucose coming from 
the blood stream. Thus, the tight coupling of astrocytic 
and neuronal metabolism may not be necessarily reflected 
by significant changes of glucose uptake to the glial cells. 
For the last twenty years the brain energy 
metabolism has been analysed in the context of the 
astrocyte-neuron lactate shuttle (ANLS) hypothesis 
which assumes that glucose is oxidised in astrocytes to 
lactate and lactate is used by neurons to fulfil their energy 
requirements [2, 3]. However, it has also been shown that 
degradation of glycogen, but not glucose, in astrocytes is 
a prerequisite for memory formation [25, 26]. The origin 
of glucosyl units for glycogen synthesis has not been 
intensively studied but it is commonly believed that they 
originate from blood-derived glucose. Our present findings 
lead to conclusion that the higher capacity of astrocytes 
to degrade glycogen to support neuronal plasticity is not 
associated with their higher capacity to take up glucose.
A molecular mechanism by which biological 
information induced by TTR is transmitted within a cell 
is not fully understood among others, in view of fact 
that membrane receptor for TTR is thus far unidentified. 
However, it has been shown that TTR may bind megalin 
(LRP-2) [27, 28], IGF-IR (insulin-like growth factor 1 
receptor) [29] and RAGE (receptor for advanced glycation 
end products) [30]. Interestingly, it has been demonstrated 
that megalin-dependent TTR internalization by sensory 
neurons was necessary for the neuritogenic activity [31] 
and that TTR-activated megalin stimulated intracellular 
pathways, such as ERK1/2 and AKT, leading to the 
activation of transcription factor CREB [32]. The most 
recent studies have revealed that in hippocampus, TTR 
promoted neurite outgrowth in a ligand (T4 and retinol)-
independent manner via phosphorylation of CREB [33].
The results presented here support the findings 
that free TTR may activate CREB. We observed that 
activation of cAMP synthesis and inhibition of PKA, 
respectively, stimulated and downregulated PKM1/2 level 
in TTRtreated astrocytes. On the other hand, the inhibition 
of PI3K/AKT signalling significantly increased PKM1/2 
level in TTR-treated cells. Notably, the pharmacological 
block of GSK3, a target of inhibitory action of AKT (for 
a review, see [34, 35]) and an activator (synergistically 
with PKA) of CREB [36, 37], strongly downregulated 
the expression of PKM1/2. Evidently, the regulation of 
PKM1/2 in astrocytes by the cAMP/PKA and the PI3K/
AKT pathways is antagonistic. 
The involvement of cAMP/PKA pathway in the 
induction of astrocyte-specific PFK and PK expression but 
not HK elevation is enigmatic. From the functional point 
of view it makes sense that TTR/cAMP activates only 
these steps of glycolysis which are engaged in glycogen 
degradation, not affecting glucose uptake
However, cAMP is a pleiotropic mediator and previous 
studies have demonstrated that CREB, a cAMP downstream 
effector, may regulate expression of mammalian HK 
(hexokinase 2 isozyme) [38]. On the other hand, a newer 
study has suggested that CREB may be a basic transcription 
factor for HK expression [39]. Since brain is the organ of the 
highest basal level of glycolytic capacity [40], an increase in 
cAMP/PKA activity in astrocytes may not be able to further 
elevate the expression of HK1, because the level of HK1 
already reached its maximum.
Insulin/IGF-I-activation of the PI3K/AKT pathway 
is associated with acceleration of energy metabolism and is 
reflected by an increase in glucose uptake [41–43]. Thus, 
the antagonistic effect of TTR on the cAMP/PKA and the 
PI3K/AKT pathways is in line with our observation that 
TTR stimulation of astrocytic metabolism is associated 
with a activation of glycolytic enzymes which degrade 
glycogen-derived glucosyl units (PFK, PKM) but not of 
enzymes stimulating glucose uptake (HK1).
Recent studies have demonstrated that TTR may act 
via the IGF-IR signalling pathway synergistically with IGFI 
[44]. However, our results revealed that supplementation 
with IGF-I did not affect metabolism of neither the FM-
treated nor the CM-treated cells. We also did not observe 
any changes in PKM1/2 level when mTOR or p38 kinases 
were inhibited. The lack of the effect of IGF-I stimulation 
on PKM1/2 expression suggests that in astrocytes, the 
regulation of glycolytic capacity and neurite outgrowth 
are independently mediated by different TTR-related 
mechanisms although, supposedly, in the both phenomena, 
the final decisive role plays the activation of CREB.
Our studies also revealed that the inhibition of FAK 
significantly lowered PKM1/2 expression in the CM-treated 
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cells. Just recently, it has been shown that FAK activation 
by IGF-I was involved in the increase of the expression of 
several glycolytic genes, among them PKM2, in pancreatic 
adenocarcinoma [45]. Results presented here excluded the 
possibility that IGF-I may stimulate expression of PKM1/2 
and further studies are required to elucidate the mechanism 
of FAK-dependent elevation of glycolysis in astrocytes. A 
diagram depicting a mechanism of TTR induced signalling 
is presented in Figure 7.
Studying the effect of the CM medium on astrocytic 
metabolism we also found that the CM, but not TTR, 
activated the expression of ALDOA. This suggests that 
not only TTR but also other soluble molecules released 
from neurons participate in the regulation of astrocytic 
metabolism. Our preliminary results showed that molecular 
mass of ALDOA expression activator is below 10 kDa (data 
not shown). Interestingly, the activation was evident after 
24 h incubation of astrocytes with the CM. However, after 
the next 24 h the FM was also able to stimulate ALDOA 
expression, which suggests that regulator of ALDOA 
expression is present also in the fresh neuronal medium, 
however, its concentration is lower than in the CM.
In conclusion, our results provide strong evidence 
that TTR is the neuron-derived factor which can specifically 
stimulate glycolysis in astrocytes in the T4 and retinol-
independent manner. The impact of TTR appears to 
be restricted to the two of three regulatory enzymes of 
glycolysis, PFK and PKM, which suggests that TTR 
is involved in the formation of the astrocyte glycogen-
neuronal mitochondria metabolic pathway of energy 
production which is required for memory formation [1, 46]. 
MATERIALS AND METHODS
Cell culture and neuron-conditioned medium 
preparation
All the procedures were approved by the Local 
Ethical Commission and every effort was made to 
minimize the number of animals used for the experiments. 
All cell cultures were maintained at 37°C in a humidified 
atmosphere with 5% CO2.
Hippocampal astrocytes and neurones cultures 
were prepared from newborn Wistar rats and cultured 
as described previously [4]. To avoid contamination 
of cultures with neurons and fibroblasts, hippocampal 
astrocytes were subcultured 2 times [47]. 
Neurons were cultured for 14–16 days in fresh 
neuronal medium (FM: Neurobasal-A, 2% B-27 
Supplement, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 
0.5 mM glutamine, 12.5 μM glutamate, and 25 μM 
βmercaptoethanol), then the neuron-conditioned medium 
(CM) was collected, filtered through 0.22 μm filters and 
stored at –80°C until used.
For in situ hybridization and immunofluorescent 
experiments astrocytes were seeded at a density of 
2.0–3.0 104/cm2 onto glass coverslips covered with poly-
L-lysine (1 mg/mL) and laminin (2.5 μg/mL) and were 
Figure 7: Mechanism of TTR-induced signaling. Interaction of TTR with its receptor (TTR-R) triggers signaling cascade leading 
to stimulation of glucose metabolism in astrocytes. TTR activates CREB via the cAMP/PKA pathway which results in upregulation of PK 
and PFK expression. The action of TTR is antagonized by the PI3K/AKT pathway, by inhibition of GSK3 activity.
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cultured for 24 h before the experiments. For ATP assay 
and activity measurement the cells were cultured in their 
specific medium to 80% confluence.
To check the metabolic changes in astrocytes by 
neuron-derived molecule(s) [4] astrocytes were incubated 
for 24 h (or 48 h in some experiments) in the CM. In 
control experiments, the FM was used.
To get some insight into the chemical nature and 
the range of the molecular weights of the regulatory 
factors released by neurons into the culture medium, the 
CM samples were heated for 5 min at 45°C or 65°C or 
were filtered through Vivaspin® filters (EQUIMED S.J.). 
The filtrations resulted in a separation of the CM samples 
into two fractions: one containing low molecular weight 
compounds (<30 kDa) and the second, containing both, 
low and high molecular weight molecules (0–100 kDa). 
In order to check the role of TTR and its cargo (retinol, 
T4) on the expression of metabolic proteins in astrocytes, the 
FM or the CM medium was supplemented with 20 μg/mL 
(36.4 nM) of human plasma TTR, 1 μM T4 or 1 μM retinol. 
In another set of experiments, astrocytes were incubated 
in the CM depleted of TTR by immunoprecipitation (IP). 
Briefly, the CM samples were incubated with rabbit anti-
TRR antibodies (1:200; Novus Biologicals cat. no. NBP1-
50256) overnight at 4°C with gentle agitation, then protein 
G-coupled Sepharose beads (Roche) were added and 
incubated overnight at 4°C with agitation. Subsequently, 
the suspension was centrifuged at 4,000 rpm for 2 min. The 
supernatant was filtered through 0.22 μm filter and used as 
the “medium post-IP”. In a control reaction, the primary 
antibodies were omitted. The results of the controls are 
shown in (Supplementary Figure 4). 
To ascertain whether the effect of the CM and TTR 
on the expression of PKM1/2 was unique for astrocytes, 
we examined the expression of PKM1/2 in lung cancer 
cells (the KLN205 cell line), secondary cultures of human 
skin fibroblasts and immortalized epithelial cells (the 
ME16C cell line) seeded in the CM or the FM medium 
supplemented with TTR. Before the stimulation, the cells 
were cultured in their specific media up to 80% confluence.
To determine which signalling pathways were 
engaged in the regulation of the astrocyte energy 
metabolism, the cells growing for 24 h in the CM or in 
the FM supplemented with 36.4 nM TTR, were treated 
for the next 24 h with one of the specific kinase inhibitors: 
wortmannin (PI3K inhibitor; 2.3 μM), rapamycin 
(mTOR inhibitor; 0.01 μM), AKT inhibitor IV (AKT 
inhibitor; 1 μM), FAK inhibitor 14 (FAK inhibitor; 1 μM), 
SB202190 (p38 inhibitor, 50 μM), SB216763 (GSK3 
inhibitor, 5 μM), KT5720 (PKA inhibitor; 20 μM) or 
with metabolic stimulators: forskolin (adenylyl cyclase 
activator, 10 μM) or IGF-I (13 nM) and the expression of 
metabolic proteins were tested. 
Fluorescent in situ hybridization (FISH)
5′-end Cy3-labelled oligonucleotides complementary 
to rat mRNA sequences for PKM1/2 (Cy3AATGG 
TACAGATGATCCCAGTGTTGCGGGCCGTGATGGG 
T), PFKP (Cy3-TCAAACACTCCTTT CCCTTCCTCTGA 
GTAGAGCTGGTAGA) and HK1 (Cy3-AAGTGGGCCA 
GGGTTTCCTCAATCTGCCGG TGCTGCTCAG) were 
synthesized by Sigma-Aldrich. FISH was performed 
according to Mamczur et al. [4]. In control reactions, the 
oligonucleotide probes were omitted. The results of the 
controls are shown in (Supplementary Figure 1). 
Immunofluorescence 
The immunofluorescence studies were performed 
as described previously [4]. The cells were fixed, 
permeabilized and incubated with the primary antibodies: 
goat anti-pyruvate kinase M1/M2 (anti-PKM1/2; 
1:1000; Acris Antibodies GmbH cat. no. R1108P), 
rabbit anti-aldolase A (anti-ALDOA; 1:500; produced 
and tested as described previously [48, 49]), rabbit 
anti-phosphofructokinase P (anti-PFKP; 1:200; Novus 
Biologicals cat. no. NBP1-19585), rabbit anti-hexokinase 
1 (anti-HK1; 1:200; Abcam cat. no. AB150423), rabbit 
anti-monocarboxylate transporter 4 (anti-MCT4; 1:100; 
Abcam cat. no. AB74109. To analyse a morphology of 
astrocytes cultured in “neuron-conditioned” and “neuron-
unconditioned” media, glial fibrillary acidic protein 
(GFAP) was visualized with rabbit anti-GFAP antibodies 
(1:400; Sigma cat. no. G9269). The primary antibodies 
were detected with fluorophore-labelled secondary 
antibodies: rabbit anti-goat-FITC (1:1,000; Sigma cat. no. 
F9012), or goat anti-rabbit-FITC (1:500; Sigma cat. no. 
F6005). Cell nuclei were stained with DAPI. In controls, 
the primary antibodies were omitted. The results of the 
controls are shown in (Supplementary Figure 1). 
Confocal microscopy and fluorescence analysis
The confocal microscopy studies were performed 
as described previously [4]. The images were taken 
from 5 to 12 randomly selected areas. All cells observed 
in the images (about 10 cells per image) were used to 
measure the mean fluorescence. The quantification of 
the fluorescence was performed using Cell^F software 
(Olympus Soft Imaging Solutions GmbH). For analysis 
of mRNA and proteins expression, the edges of the cells 
were marked and the mean fluorescence was measured. 
All experiments were done in triplicate.
Activity measurement
PKM1/2 activity was assayed spectrophotometrically 
as described previously [40], with slight modifications. 
Enzyme activity was assayed using cellular extract obtained 
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by homogenisation of astrocytes in a lysis buffer (250 nM 
KCl, 50 mM Tris, 0.1% Triton x-100, 0.1 mM EDTA, 
0.1 mM EGTA, pH 7.4, 4oC). To avoid degradation of 
cytosolic proteins protease inhibitor cocktail (1:25, Roche) 
was added. Thereafter, the homogenate was centrifuged at 
20,000 g, at 4°C, for 20 min. The activity was measured 
in 50 mM Bis-Tris-Propane buffer with 100 mM KCl, 
0.25 mM EDTA and 10.25 mM MgCl2, pH 7.4, 37°C. 
The reaction mixture contained 0.2 mM NADH, 1.25 mM 
ADP and 1 U LDH. An enzyme activity, expressed in 
U [μmol min−1] was determined from the difference in the 
slope of NADH absorbance (340 nm; ε = 6.22 mM−1 cm−1) 
after addition of a substrate (5 mM phosphoenolpyruvate). 
All spectrophotometric measurements were performed with 
an Agilent 8453 diode array spectrophotometer. Protein 
concentrations were determined using Bradford Reagent. 
All measurements were done in triplicate.
Mass spectrometry
Media were filtered as described above. Obtained 
supernatant (fraction 30–100 kDa) was precipitated with 
TCA, resolved by 15 % SDS-PAGE and stained with 
PageBlue™ Protein Staining Solution (Thermo Fisher 
Scientistic). Acrylamide gels were then cut into 0.5 cm 
slices. In this way we obtained 16 slices (8 per each 
medium) containing separated proteins.
Protein within slices were reduced with DTT, 
alkylated with iodoacetamide and digested with trypsin 
according to the standard protocol [50]. A total of 40 ng 
of sequencing grade trypsin was added to each excised gel 
fragment, covered with 100 mM ammonium bicarbonate 
and the samples were incubated at 37°C overnight. The 
supernatant was collected and further extraction was 
performed by addition of 5% formic acid/ACN (1:1, v/v) 
followed by a second extraction step of 5% formic acid/
ACN (5:95, v/v). The combined solvent extracts were 
vacuum dried and reconstituted in 0.1% TFA, concentrated 
and desalted using C18 ZipTips (Millipore). The obtained 
peptides were analysed by MALDI-TOF/TOF using the 
Applied Biosystems 4800 Proteomics Analyser. Sample 
preparation for analysis was as follows: tryptic peptides 
were mixed 1:1 v/v with α-cyano-4-hydroxycinnamic acid 
(10 mg/mL in ACN/0.1% TFA) and spotted directly onto 
the MALDI target without chromatographic separation. 
MS spectra were calibrated using two external standards 
and tryptic autolytic peaks. Typically, each MS spectrum 
was acquired in the positive-ion reflectron mode using 400 
laser shots. A set of 6–20 ions, depending on the complexity 
of the MS1 spectrum, which had both (1) strong intensities 
and (2) were well resolved from neighbouring ions were 
analysed further. Fragmentation spectra were acquired as 
postsource decay unimolecular decompositions (collision 
gas off) using 3,000 laser shots. A fragmentation voltage of 
2 kV was used throughout the automated runs. 
The spectra were processed and analysed using the 
4000 Series Explorer v3.5.3 (Applied Biosystems) and 
ProteinPilot v4.0 (Applied Biosystems). Protein searches 
were performed against the SwissProt Homo sapiens 
protein database (release date 06032017) using Mascot 2.3 
and Paragon 4.0 platform. The database search parameters 
were: mass tolerance of 40 ppm for precursor ions and 
0.8 Da for fragment ions; trypsin digestion with two missed 
cleavages, fixed modification–carbamidomethylation (C). 
Protein identity was accepted at the 95% confidence level.
ATP measurement
ATP measurements were performed with Single 
Tube Luminometer (Microdigital) according to the 
manufacturer requirements. ATP level was determined 
in a cellular extract obtained by incubation of the cells 
in an extraction buffer (50 mM Tris, 1 mM EDTA, 
0.1% Triton X-100, pH 7.5, RT) for 10 min. The lysates 
were heated for 45s at 99°C and then centrifuged at 
10,000 g at 4°C for 10 min. Then, the supernatants were 
collected and assayed with luciferase/luciferin (Sigma) 
according to manufacturer recommendations. Protein 
concentrations were determined using Bradford Reagent. 
All measurements were performed at least in triplicate.
Western blot
Protein extracts were obtained by incubation of 
astrocytes in a lysis buffer (50 mM Tris, 0.2 mM EDTA, 
5% SDS, 50 mM DTT, pH 8.0) for 20 min at 99°C and 
centrifuged at 20,000g at 4°C for 20 min. The supernatants 
were collected and total protein concentration was 
determined using the Bradford method. The extracts (15 μg) 
were resolved by 10% SDS-PAGE, transferred to the 
nitrocellulose using a wet system and stained with Poceau S 
to test the quality of the protein transfer. Membrane was 
blocked for 1 h in 3% BSA in PBS and then incubated 
overnight at 4°C with primary antibodies diluted in 
Solution 1 from SignalBoost™ Immunoreaction Enhancer 
Kit (Millipore). Then the blot was incubated for 2 h at 
RT with secondary antibodies diluted in Solution 2 from 
SignalBoost™ Immunoreaction Enhancer Kit. Pyruvate 
kinase M1/2 was detected with goat anti-PKM1/2 antibodies 
(1:2500; Acris Antibodies GmbH cat. no. R1108P), 
secondary antibodies conjugated with biotin (1:2500; 
Sigma cat. no. B7014) and Extravidin conjugated with 
peroxidase (1:2000 in PBS; Sigma cat. no. E2886). Mouse 
anti-β-actin antibodies (1:2500; Sigma cat. no. A5441) and 
secondary antibodies conjugated with peroxidase (1:2500; 
Sigma cat. no. A4416) were used to detect β-actin which 
was used as a loading control. A peroxidase substrate, 
3,3′-diaminobenzidine (DAB), was used. 
Statistical analysis
Collected data was analysed using Microsoft 
Excel 2010. Results are expressed as mean and standard 
deviation of at least three individual experiments. For an 
evaluation of statistical significance the Student’s t-test 
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was used. A probability of P < 0.05 was considered to 
represent a significant difference. 
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